ArticleScientific reports2025
Fabrication of a low-kink-radius bilayer vascular scaffold incorporating a TPU stent fabricated via melt electrowriting and an electrospun PCL/PU/gelatin layer.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Topology-Driven Mechanical Tuning of FDM-Printed TPU Tubular Lattices with Auxetic Architectures.Micromachines · 2026Article
- Hybrid SES-MEW Scaffold Strategies: A Narrative Review of Multi-Scale Fiber Architectures for Soft and Hard Tissue Engineering.Pharmaceuticals (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study investigates the fabrication of a small-diameter bilayer vascular graft, which is an inner layer fabricated from melt-electrowriting (MEW) thermoplastic polyurethane (TPU) scaffold and an outer co-electrospun layer made of heparinized polycaprolactone (PCL)/polyurethane (PU)/gelatin, aimed at mimicking the extracellular matrix (ECM). The bilayer structure exhibited good flexibility, mechanical stability, and anti-thrombogenic properties, overcoming the drawbacks of vascular grafts, such as high kink radius and tendency toward thrombosis. MTT assays proved cytocompatibility, showing an increase in cell proliferation over 7 days, the optical density of the bilayer vascular graft increased from [Formula: see text] on day [Formula: see text] to [Formula: see text] on day [Formula: see text], respectively, due to its fibrous structure and hydrophilic properties. Live/dead and SEM assays confirmed cell viability, attachment, and endothelial layer formation on the scaffold, which provides long-term graft patency. The bilayer graft with integrated MEW structure provided the balanced mechanical and kink-radius properties (ultimate tensile strength [Formula: see text], Young's modulus [Formula: see text], suture retention [Formula: see text]) with a low kink radius ([Formula: see text]), surpassing the mechanical properties of coronary artery. A heparin release profile of 70% after 4 weeks was obtained, thus increasing anticoagulant effects. This combination of synthetic (TPU, PCL, PU) and natural (gelatin) polymers yields a biocompatible, structurally stable vascular graft, which efficiently supports endothelialization, and thus has good potential for clinical vascular applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.